Next Generation Tissue Biomarkers Market Insights, Revenue Analysis, and Future Outlook | Valuates Reports

on

Next Generation Tissue Biomarkers Market

Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights


How Strong Is the Market Growth Outlook for the Next Generation Tissue Biomarkers Market?
The next generation tissue biomarkers market size has grown rapidly in recent years. It will grow from $2.68 billion in 2024 to $3.03 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to rising demand for personalized medicine, increasing adoption of immunohistochemistry techniques, growing need for early disease detection, increasing healthcare spending, rise in diagnostic imaging technologies, rising awareness about biomarker-based diagnostics, and growing focus on companion diagnostics.

The next generation tissue biomarkers market size is expected to see rapid growth in the next few years. It will grow to $4.89 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to growing demand for multiplex biomarker assays, rising use of next-generation sequencing, increasing investment in cancer research, expanding applications of digital pathology, growing use of AI in diagnostics, a surge in clinical trials for targeted therapies, and increasing availability of tissue-based genomic data. Major trends in the forecast period include advancements in next-generation sequencing, integration of artificial intelligence (AI) in digital pathology, development of advanced mass spectrometry-based proteomics, advancements in ribonucleic acid biomarker detection technologies, and integration with cloud-based data platforms.

Claim your free report sample now:

Which Factors Are Driving Growth in the Next Generation Tissue Biomarkers Market?
The rising demand for personalized medicine is expected to propel the growth of the next generation tissue biomarkers market going forward. Personalized medicine is a medical approach that tailors treatment based on an individual's genetic makeup, lifestyle, and environmental factors. The adoption of personalized medicine is increasing due to continuous advancements in genomic technologies, as they allow for highly specific and individualized treatment strategies. The demand for personalized medicine is boosting the development of next-generation tissue biomarkers, as they provide precise and individualized information needed to tailor treatments to each patient's unique tissue profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine is driving the growth of the next generation tissue biomarkers market.

What Are the Key Segments in the Next Generation Tissue Biomarkers Market?
The next generation tissue biomarkers market covered in this report is segmented

1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers
2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies
3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications
4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations

Subsegments:
1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions
2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions
3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation
4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants
5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids

What Are the Top Trends Expected to Shape the Next Generation Tissue Biomarkers Market by 2029?
Major companies operating in the next generation tissue biomarkers market are focusing on developing advanced solutions, such as genomic-based diagnostic assays and sequencing solutions, to enhance the accuracy, speed, and personalization of cancer diagnosis and treatment. Genomic-based diagnostic assays and sequencing solutions refer to tools and techniques that examine genetic information to identify disease-related biomarkers, enabling more precise and personalized approaches to diagnosis and therapy. For instance, in August 2024, Illumina Inc., a US-based biotechnology company, received FDA approval for its TruSight Oncology Comprehensive test, along with two companion diagnostics, to rapidly match cancer patients to targeted therapies. The test profiles over 500 genes from a single tissue sample, enabling precise treatment selection for various solid tumors. It automates biomarker detection and supports 24/7 deployment, significantly reducing turnaround times and enhancing clinical efficiency, representing a modern approach to streamlining cancer diagnostics within a regulated framework.

Who Are the Leading Players in the Next Generation Tissue Biomarkers Market?
Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., and Biofidelity Ltd.

Get the full next generation tissue biomarkers market report here:

What Are the Key Regional Trends in the Next Generation Tissue Biomarkers Market?
North America was the largest region in the next generation tissue biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation tissue biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company


Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267



Follow Us On:

Comments

Post a Comment